Aethlon Medical Inc (AEMD) Stock Price & Analysis
Aethlon Medical Inc (AEMD) fell 2.63% to USD 0.58 as of July 25, 2026 at 07:00 UTC, according to Nexqual real-time market data.
AEMD last closed at USD 0.6; the session ranged USD 0.58–0.61 on volume of 61,206 shares. Market capitalization is $1.54M, with a 52-week range of USD 0.58–27.4 (NCM). Source: Nexqual, July 25, 2026 at 07:00 UTC.
Key Statistics (as of July 25, 2026 at 07:00 UTC)
| Price | USD 0.58 |
|---|---|
| Change | ▼ 2.63% (down) |
| Previous Close | USD 0.6 |
| Open | USD 0.6 |
| Day Range | USD 0.58 – 0.61 |
| 52-Week Range | USD 0.58 – 27.4 |
| Volume | 61,206 shares |
| Market Cap | $1.54M |
| Exchange | NCM |
Technical Analysis (AEMD)
Nexqual's technical model rates AEMD "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.01 (oversold) |
| vs SMA50 | Below (USD 1.49) |
| MACD | -0.25 (negative) |
Analyst Ratings (AEMD)
Wall Street analysts rate AEMD "None" based on 2 analysts, with a mean price target of USD 3.25 (range USD 1.5–5), per Nexqual as of July 25, 2026 at 07:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 3.25 |
| High Target | USD 5 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (AEMD)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.81 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -2.45 vs est -2.01 ▼ miss |
| 2025-09-30 | USD -3.74 vs est -1.7 ▼ miss |
| 2025-06-30 | USD -8.5 vs est -7.3 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Financials & Fundamentals (AEMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -142.89% |
| Debt / Equity | 10.54 |
| Current Ratio | 3.85 |
| Total Cash | $5.03M |
| Total Debt | $514,816 |
| Free Cash Flow | $-4.54M |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Financial Health Score (AEMD)
Nexqual rates Aethlon Medical Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $5M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -143%, ROA -66.6% |
Ownership (AEMD)
| Insider Ownership | +5.15% |
|---|---|
| Institutional Ownership | +5.82% |
| Shares Outstanding | 2.63M |
| Float | 2.35M |
| Short % of Float | +8.70% |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Leadership (AEMD)
Aethlon Medical Inc is led by James B. Frakes (age 68), CEO, CFO, Chief Accounting Officer, Secretary & Director, per Nexqual as of July 25, 2026 at 07:00 UTC.
| CEO, CFO, Chief Accounting Officer, Secretary & Director | James B. Frakes (age 68) |
|---|
Major Backers & Investors (AEMD)
Notable institutional backers of Aethlon Medical Inc include Fidelity, Ikarian Capital, LLC, Shay Capital LLC, according to Nexqual as of July 25, 2026 at 07:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.85% |
| Ikarian Capital, LLC | 0.61% |
| Shay Capital LLC | 0.6% |
| Xtx Topco Ltd | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.03% |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
From Aethlon Medical Inc's Latest SEC 10-K Filing (filed 2026-06-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Following the filing of the amendment, the Company may offer and sell shares of its common stock having an aggregate offering price of up to approximately $542,716 pursuant to its ATM facility.   Intellectual Property   We rely on a combination of patents, trade secrets, know-how, trademarks, and confidentiality agreements to protect our proprietary technologies, including the Hemopurifier platform.
- Our patent portfolio relates primarily to extracorporeal removal technologies, viral and exosome-related applications, and related therapeutic methods.   We also maintain trademark registrations for Hemopurifier and Aethlon Medical in the United States, trademark protection for Hemopurifier in India, and international trademark protection for SANSAGITTA in multiple jurisdictions, including Australia, Canada, the European Union, the United Kingdom, and India.
- In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation, or QSR.
Partnerships
- Payors may include the Centers for Medicare & Medicaid Services, or CMS, which administers the Medicare program and works in partnership with state governments to administer Medicaid, other government programs and private insurance plans.
- Therefore, coverage and reimbursement can differ significantly from payor to payor.   Manufacturing   Historically, manufacturing of our Hemopurifier was conducted in collaboration with a contract manufacturer based in California, operating under current Good Manufacturing Practice, or cGMP, regulations promulgated by the FDA. Our contract manufacturer is registered with the FDA.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NNVC | NanoViricides, Inc. | USD 1.48 | ▼ 2.63% |
| BNBX | BNB Plus Corp. | USD 0.09 | ▼ 18.18% |
| GOVX | GeoVax Labs, Inc. | USD 0.73 | ▼ 21.9% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:00 UTC. This page is informational and not investment advice.